Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07217054 · ClinicalTrials.gov registry record

Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder

A clinical trial of Parkinson Disease and PARKINSON DISEASE (Disorder), sponsored by CND Life Sciences.

Recruiting
Registry status
40
Enrollment target
1
Study location

NCT07217054 is a study of Parkinson Disease and PARKINSON DISEASE (Disorder) that is actively recruiting participants, run by CND Life Sciences. The registered enrollment target is 40 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07217054, a study of Parkinson Disease and PARKINSON DISEASE (Disorder), is actively recruiting participants, sponsored by CND Life Sciences.

RECRUITING
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease or REM Sleep Behavior Disorder (RBD). The main question it aims to answer is: Can doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease and RBD? Currently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems and RBD by loss of muscle atonia during REM sleep, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.

Study Locations (1)

Connecticut

  • Digestive Disease Associates - Branford

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-11-04
Est. Completion 2029-10

Sponsor

CND Life Sciences

8 total trials

What the Registry Record Tells You About NCT07217054

The ClinicalTrials.gov registry entry for NCT07217054 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is CND Life Sciences, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.

NCT07217054 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT07217054 about?

NCT07217054 is a clinical study titled "Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder". The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease or REM Sleep Behavior Disorder (RBD). The main question it aims to answer is: Can doctors find a protein called alpha-synuclein in colon ti...

What is the current status of trial NCT07217054?

This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2025-11-04. Estimated completion is 2029-10.

What conditions does trial NCT07217054 study?

This clinical trial studies the following conditions: Parkinson Disease, PARKINSON DISEASE (Disorder), Parkinson, Parkinson s Disease.

Who is sponsoring clinical trial NCT07217054?

This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07217054 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.